ASCO 2023 | Optimizing outcomes in PSA recurrent prostate cancer

Tian Zhang, MD, UT Southwestern Medical Center, Dallas, TX, describes how survival rates can be improved in patients with PSA recurrent prostate cancer. Addition of androgen deprivation therapy (ADT), apalutamide with radiation therapy and docetaxel have shown promising clinical activity. However, patients who are PSMA positive in this setting remain an unmet need. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.